Results 171 to 180 of about 10,520,123 (362)

Dorsal Hump Reduction Based on the New Ethmoidal Point Classification: A Clinical and Radiological Study of the Keystone Area in 138 Patients [PDF]

open access: bronze, 2020
Miguel Gonçalves Ferreira   +7 more
openalex   +1 more source

CMF Classification [PDF]

open access: yesCraniomaxillofacial Trauma & Reconstruction, 2014
Paul N, Manson   +2 more
openaire   +2 more sources

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

open access: yesActa Neuropathologica, 2016
D. Louis   +9 more
semanticscholar   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

open access: yesMolecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad   +17 more
wiley   +1 more source

Evaluation of sampling frequency, window size and sensor position for classification of sheep behaviour

open access: gold, 2018
E. K. Walton   +8 more
openalex   +1 more source

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

open access: yesMolecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande   +11 more
wiley   +1 more source

Aggressive prostate cancer is associated with pericyte dysfunction

open access: yesMolecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy